Arrowpoint Investment Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Citigroup
C
|
+$30.6M |
| 2 |
Goldman Sachs
GS
|
+$30.2M |
| 3 |
ExxonMobil
XOM
|
+$26.8M |
| 4 |
Global Payments
GPN
|
+$26.4M |
| 5 |
NVIDIA
NVDA
|
+$25.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASE Group
ASX
|
+$3.89M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$2.71M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$2.01M |
| 4 |
Pfizer
PFE
|
+$2M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$1.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 28.72% |
| 2 | Healthcare | 18.58% |
| 3 | Financials | 14.08% |
| 4 | Industrials | 12.67% |
| 5 | Technology | 12.03% |
Similar funds
Arrowpoint Investment Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Arrowpoint Investment Partners held 167 positions worth $459M, up 308% from $113M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Arrowpoint Investment Partners deployed $245M of net new capital in Q2 2026, opening 86 new positions and adding to 23 existing holdings. Its largest new stake was Citigroup: 235,033 shares worth $32.9M.
By sector, the portfolio is most concentrated in Miscellaneous at 29% of assets, down from 45% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $2.01M trimmed.
- Arrowpoint Investment Partners's largest Q2 2026 buy was Citigroup: 235,033 shares worth $32.9M.
- Arrowpoint Investment Partners added most to Insmed in Q2 2026, an estimated $2.8M increase.
- Arrowpoint Investment Partners's biggest Q2 2026 reduction was Ionis Pharmaceuticals, cutting an estimated $2.01M.
- Arrowpoint Investment Partners fully exited ASE Group in Q2 2026, selling an estimated $3.89M.
- Arrowpoint Investment Partners's ten largest holdings make up 64% of its $459M portfolio in Q2 2026.
- Arrowpoint Investment Partners opened 86 new positions and closed 38 in Q2 2026.
- Arrowpoint Investment Partners's portfolio value rose 308% quarter-over-quarter to $459M.
Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.